Skip to main content

Fangzhou Issues Positive Profit Forecast as AI-Driven Chronic Care Model Delivers First Full-Year Profit

Written by Customer Service on . Posted in Public Companies.

SHANGHAI, Jan. 27, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, issued a positive profit forecast for 2025, citing stronger-than-expected revenue growth and its first year of full profitability, underscoring the commercial viability of its “AI + chronic care services” model.

In a filing released on January 25, the company said it expects full-year revenue for 2025 to reach between RMB 3.5 billion and RMB 3.55 billion, representing year-on-year growth of approximately 30%. Fangzhou also forecast a net profit of RMB 7 million to RMB 10 million, marking a transition to comprehensive profitability after achieving adjusted profitability in 2024.

The company attributed the revenue increase primarily to the continued expansion of its chronic disease management services built around trusted doctor–patient relationships, as well as the upgrading of its platform through AI technologies. These factors have attracted a growing number of physicians and patients, driving sustained growth in its consumer-facing business. The turnaround to profitability was also supported by higher revenue scale and a reduction in equity-settled and share-based payments.

Fangzhou said the earnings improvement reflects a qualitative shift in its business fundamentals, validating the long-term sustainability of its chronic disease management model. The Company operates one of China’s largest “AI + chronic disease management” platforms, benefiting from rising healthcare demand amid an aging population and increasing preference for accessible, technology-enabled medical services.

In 2025, the Company completed a key strategic upgrade to its “AI + H2H (Hospital-to-Home)” model, applying AI across the entire service chain. In September 2025, Fangzhou began benchmarking against OpenEvidence and accelerated its large-model deployment, completing key technical positioning nearly six months ahead of many peers, further strengthening its leadership in AI-powered healthcare.

External research institutions have also taken note. Citi Research initiated coverage on Fangzhou in mid-2025 with a “Buy” rating and a target price of HK$8.50. Separately, Gelonghui Research Institute said in an early-2026 report that the Company’s revenue is expected to reach HK$3.5 billion in 2025 and HK$4.8 billion in 2026, adding that Fangzhou is entering a period of value re-rating driven by scale expansion and improving profitability.

Looking ahead, Fangzhou will continue to refine its AI + H2H full-cycle smart healthcare ecosystem, deepen technology research and service innovation, and leverage its platform capabilities to support China’s “Healthy China 2030” initiative while setting benchmarks for high-quality development in the digital healthcare industry.

About Tencent Healthcare
Tencent Healthcare, as Tencent’s healthcare service platform, leverages the WeChat ecosystem and artificial intelligence technologies to build an integrated service system.

About Fangzhou Inc.
Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians (as of June 30, 2025). The Company specializes in delivering tailored medical care and AI-enabled precision medicine solutions. For more information, visit https://investors.jianke.com.

Media Contact
For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.